Joint association of urinary sodium and potassium excretion with cardiovascular events and mortality: prospective cohort study
| Primer Autor |
O'Donnell, Martin
|
| Co-autores |
Mente, Andrew
Rangarajan, Sumathy
McQueen, Matthew J.
O'Leary, Neil
Yin, Lu
Liu, Xiaoyun
Swaminathan, Sumathi
Khatib, Rasha
Rosengren, Annika
Ferguson, John
Smyth, Andrew
Lopez-Jaramillo, Patricio
Diaz, Rafael
Avezum, Alvaro
Lanas, Fernando
Ismail, Noorhassim
Yusoff, Khalid
Dans, Antonio
Iqbal, Romaina
Szuba, Andrzej
Mohammadifard, Noushin
Oguz, Atyekin
Yusufali, Afzal Hussein
Alhabib, Khalid F.
Kruger, Iolanthe M.
Yusuf, Rita
Chifamba, Jephat
Yeates, Karen
Dagenais, Gilles
Wielgosz, Andreas
Lear, Scott A.
Teo, Koon
Yusuf, Salim
|
| Título |
Joint association of urinary sodium and potassium excretion with cardiovascular events and mortality: prospective cohort study
|
| Editorial |
BMJ PUBLISHING GROUP
|
| Revista |
BMJ-BRITISH MEDICAL JOURNAL
|
| Lenguaje |
English
|
| Tipo de Recurso |
artículo original
|
| Derecho de Acceso |
acceso abierto
|
| Description |
The funders of the study had no role in its design or conduct, in the collection, analysis, or interpretation of the data, or in the writing of the manuscript. The current analyses were supported by funding from the European Research Council (COSIP grant, 640580) and Heart and Stroke Foundation of Ontario. SY is supported by the Mary W Burke endowed chair of the Heart and Stroke Foundation of Ontario. The PURE study is an investigator initiated study that is funded by the Population Health Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, Support from CIHR's Strategy for Patient Oriented Research, through the Ontario SPOR Support Unit, as well as the Ontario Ministry of Health and Long-Term Care and through unrestricted grants from several pharmaceutical companies (with major contributions from Astra Zeneca (Canada), Sanofi-Aventis (France and Canada), Boehringer Ingelheim (Germany and Canada), Servier, and GSK), and additional contributions from Novartis and King Pharma and from various national or local organisations in participating countries. These include Argentina: Fundacion ECLA; Bangladesh: Independent University, Bangladesh and Mitra and Associates; Brazil: Unilever Health Institute, Brazil; Canada: Public Health Agency of Canada and Champlain Cardiovascular Disease Prevention Network, Canadian Institutes of Health Research (Catalyst Grant: eHealth Innovations-grant No: 126524); Chile: Universidad de La Frontera (Internal Registry DI13-PE11); China: National Center for Cardiovascular Diseases; Colombia: Colciencias, grant No: 6566-04-18062; India: Indian Council of Medical Research; Malaysia: Ministry of Science, Technology and Innovation of Malaysia grant No 100-IRDC/BIOTEK 16/6/21 (13/2007), grant No 07-05-IFN-BPH 010, Ministry of Higher Education of Malaysia grant No 600-RMI/LRGS/5/3 (2/2011), Universiti Teknologi MARA, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur Malaysia. CRIM, University Kebangsaan Malaysia; Occupied Palestinian Territory: The United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA), occupied Palestinian territory; International Development Research Centre (IDRC), Canada; Peru: National Heart, Lung and Blood Institute (HHSN268200900033C), National Cancer Institute (1P20CA217231), Wellcome (103994/Z/14/Z); Philippines: Philippine Council for Health Research & Development (PCHRD); Poland: Polish Ministry of Science and Higher Education grant No 290/W-PURE/2008/0, Wroclaw Medical University, Wroclaw Medical University, statutory activity Saudi Arabia: Saudi Heart Association, The Deanship of Scientific Research at King Saud University, Riyadh, Saudi Arabia (Research group No: RG -1436-013); South Africa: The North-West University, SANPAD (SA and Netherlands Programme for Alternative Development), National Research Foundation, Medical Research Council of SA. The SA Sugar Association (SASA), Faculty of Community and Health Sciences (UWC); Sweden: grants from the Swedish state under the Agreement concerning research and education of doctors; the Swedish Heart and Lung Foundation; the Swedish Research Council; the Swedish Council for Health, Working Life and Welfare, King Gustaf V:s and Queen Victoria Freemason's Foundation, AFA Insurance; Tanzania: Pamoja Tunaweza Health Research Centre (Tanzania), Queen's University, Department of Medicine; Turkey: Metabolic Syndrome Society, Astra Zeneca, Turkey; UAE: Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences, and Dubai Health Authority, Dubai UAE.
|
| doi |
10.1136/bmj.l772
|
| Formato Recurso |
pdf
|
| Ubicación del archivo | |
| Disciplinas de la OCDE |
Medicina General e Interna
Salud Pública y Ambiental
Nutrición y Dietética
Sistema Cardiovascular y Cardiaco
|
| Id de Web of Science |
WOS:000461751600003
|
| Access Rights |
acceso abierto
|
| Derechos de acceso |
acceso abierto
|
| Formato |
pdf
|
| Título de la cita (Recomendado-único) |
Joint association of urinary sodium and potassium excretion with cardiovascular events and mortality: prospective cohort study
|
| Identificador del recurso (Mandatado-único) |
artículo original
|
| Versión del recurso (Recomendado-único) |
version publicada
|
| ISSN |
0959-535X
|
| Tipo de ruta |
dorada
verde
|
- Colecciones
- Colección Publicaciones Científicas